Raloxifene increases bone mineral density in postmenopausal women but decreases it in premenopausal women. The studies show that premenopausal women detected cuteness better than same aged postmenopausal women. AG is not an effective ovarian steroidogenesis inhibitor in premenopausal women. In premenopausal women, raloxifene increases levels of follicle-stimulating hormone (FSH) and estradiol. Elagolix should not be used in premenopausal women with known osteoporosis. At the same time, raloxifene has minimal antiestrogenic effect in the uterus in premenopausal women. The drug is contraindicated in premenopausal women, which of course includes pregnant and lactating women. Similarly, an adrenalectomized premenopausal woman showed incompletely diminished circulating pregnenolone levels. In one study, premenopausal women who exhibited symptoms of iron deficiency were given endoscopies. Conversely, medical castration has been found to partially suppress pregnenolone levels in premenopausal women. Vulvar Vestibulitis Syndrome (VVS) is the most common subtype of vulvodynia that affects premenopausal women. Elagolix dose- and duration-dependently decreases BMD in premenopausal women with long-term therapy. The condition affects about 6% of premenopausal women. Otherwise if a woman is healthy and premenopausal it is considered uncomplicated.